Patent 9585921 was granted and assigned to Seres Therapeutics on March, 2017 by the United States Patent and Trademark Office.
Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.